Eledon Pharmaceuticals, Inc.
ELDN
$2.82
-$0.11-3.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.92% | -15.15% | -8.75% | 33.36% | 38.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.75% | 11.32% | 17.96% | 53.80% | 87.40% |
| Operating Income | 3.75% | -11.32% | -17.96% | -53.80% | -87.40% |
| Income Before Tax | -753.62% | -319.57% | -27.49% | -266.27% | 113.89% |
| Income Tax Expenses | -91.88% | -91.88% | -91.88% | -- | -- |
| Earnings from Continuing Operations | -773.09% | -310.26% | -26.07% | -268.26% | 113.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -773.09% | -310.26% | -26.07% | -268.26% | 113.49% |
| EBIT | 3.75% | -11.32% | -17.96% | -53.80% | -87.40% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -195.64% | -125.69% | 47.30% | 17.69% | 127.72% |
| Normalized Basic EPS | -255.27% | -184.20% | 43.32% | 19.48% | 119.56% |
| EPS Diluted | 19.41% | 67.71% | 82.72% | 68.25% | 67.11% |
| Normalized Diluted EPS | -283.17% | -114.72% | 48.22% | 24.73% | 116.58% |
| Average Basic Shares Outstanding | 44.49% | 50.11% | 68.42% | 94.44% | 107.77% |
| Average Diluted Shares Outstanding | 42.66% | 47.95% | 65.42% | 90.12% | 110.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |